4Filing Date: Aug 20, 2026

Core Scientific (CORZ)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0000905148-26-003841
Total Value$134.4K
Trades1
Insiders1

Transaction Details

Weiss Eric Stanton
Director·Direct
Buy · Acquire
Common Stock
Shares+7.00K
Price$19.19
Total Value$134.4K
Shares Owned After259.26K
Transaction DateAug 18, 2026
Footnotes ▸

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.785 to $19.595, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

Post-Transaction Holdings

Weiss Eric Stanton · Director
SecuritySharesChange
Common Stock259.26K+7.00K (2.77%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-08-18 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Core Scientific, Inc./tx (CORZ) CIK: 0001839341 --- Reporting Owner --- Name: Weiss Eric Stanton CIK: 0002009491 Role: Director --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-08-18 | Code: P (Open market purchase) Shares: +7,000 | Price: $19.19 Total Value: $134,358.00 Shares Owned After: 259,262 | Ownership: D (Direct) Footnotes: [F1] The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.785 to $19.595, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. --- Footnotes (Complete Index) --- F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.785 to $19.595, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. --- Signature --- /s/ /s/ Todd DuChene, as Attorney-in-Fact (2026-08-20)

keid analysis is for reference only and does not constitute investment advice.